- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00552058
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
10 luglio 2018 aggiornato da: UCB Pharma
Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
439
Fase
- Fase 3
Accesso esteso
A disposizione al di fuori della sperimentazione clinica.
Vedi record di accesso esteso.
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Adelaide, Australia
-
Bankstown, Australia
-
Clayton, Australia
-
Fitzroy, Australia
-
Fremantle, Australia
-
Garran, Australia
-
-
New South Wales
-
Concord, New South Wales, Australia
-
-
Victoria
-
Box Hill, Victoria, Australia
-
Footscray, Victoria, Australia
-
Parkville, Victoria, Australia
-
-
-
-
-
Wien, Austria
-
-
-
-
-
Bonheiden, Belgio
-
Brussels, Belgio
-
Gent, Belgio
-
Leuven, Belgio
-
Liege, Belgio
-
Roeselare, Belgio
-
-
-
-
-
Curitiba, Brasile
-
Goiania, Brasile
-
Porto Alegre, Brasile
-
Rio de Janeiro, Brasile
-
Santo-Andre, Brasile
-
Santos, Brasile
-
Sao Paulo, Brasile
-
-
MG
-
Belo-Horizonte, MG, Brasile
-
-
-
-
-
Calgary, Canada
-
-
Alberta
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Kelowna, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
Kingston, Ontario, Canada
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
-
-
-
Hradec Kralove, Cechia
-
Hradek Kralove, Cechia
-
Praha 7, Cechia
-
Usti Nad Orlici, Cechia
-
Zlin, Cechia
-
-
-
-
-
Santiago, Chile
-
Vina del Mar, Chile
-
-
-
-
-
Tallin, Estonia
-
Tartu, Estonia
-
-
-
-
-
Kazan, Federazione Russa
-
Moscow, Federazione Russa
-
St. Petersburg, Federazione Russa
-
-
-
-
-
Mikkeli, Finlandia
-
-
-
-
-
Berlin, Germania
-
Frankfurt, Germania
-
Freiburg, Germania
-
Homburg, Germania
-
Jena, Germania
-
Kiel, Germania
-
Munchen, Germania
-
Ulm, Germania
-
Wilhelmshaven, Germania
-
-
-
-
-
Beer Sheva, Israele
-
Haifa, Israele
-
Holon, Israele
-
Jerusalem, Israele
-
Kfar Saba, Israele
-
Petha Tikva, Israele
-
Rehovot, Israele
-
Tel Aviv, Israele
-
Zerifin, Israele
-
-
-
-
-
Bologna, Italia
-
Padova, Italia
-
Roma, Italia
-
-
-
-
-
Riga, Lettonia
-
Valmiera, Lettonia
-
-
-
-
-
Auckland, Nuova Zelanda
-
Christchurch, Nuova Zelanda
-
Hamilton, Nuova Zelanda
-
-
Auckland
-
Milford, Auckland, Nuova Zelanda
-
-
Wellington
-
Newton, Wellington, Nuova Zelanda
-
-
-
-
-
Czestochowa, Polonia
-
Lodz, Polonia
-
Warszawa, Polonia
-
Wroclaw, Polonia
-
-
-
-
-
Bucharest, Romania
-
Cluj Napoca, Romania
-
Constanta, Romania
-
-
-
-
Alabama
-
Pell City, Alabama, Stati Uniti
-
-
Colorado
-
Colorado Springs, Colorado, Stati Uniti
-
Lakewood, Colorado, Stati Uniti
-
Littleton, Colorado, Stati Uniti
-
-
Florida
-
Hollywood, Florida, Stati Uniti
-
Jacksonville, Florida, Stati Uniti
-
New Port Richey, Florida, Stati Uniti
-
Winter Park, Florida, Stati Uniti
-
-
Illinois
-
Chicago, Illinois, Stati Uniti
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti
-
Monroe, Louisiana, Stati Uniti
-
-
Maryland
-
Annapolis, Maryland, Stati Uniti
-
Towson, Maryland, Stati Uniti
-
-
Michigan
-
Chesterfield, Michigan, Stati Uniti
-
West Bloomfield, Michigan, Stati Uniti
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti
-
Cleveland, Ohio, Stati Uniti
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Stati Uniti
-
-
Tennessee
-
Germantown, Tennessee, Stati Uniti
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti
-
-
Washington
-
Seattle, Washington, Stati Uniti
-
-
-
-
-
Dniepropetrovsk, Ucraina
-
Donetsk, Ucraina
-
Kiev, Ucraina
-
Kyiv, Ucraina
-
Lviv, Ucraina
-
Simferopol, Ucraina
-
-
-
-
-
Budapest, Ungheria
-
Gyor, Ungheria
-
Nagykanizsa, Ungheria
-
Szeged, Ungheria
-
Szombathely, Ungheria
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 75 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- male/female
- 18 - 75 years inclusive
- diagnosis of Crohn's disease confirmed
- moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
- no previous treatment with anti-tumor necrosis factor (anti-TNF) medications
Exclusion Criteria:
- previous participation in a certolizumab pegol study
- general exclusion criteria as common for studies in this indication
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
|
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Altri nomi:
|
|
Comparatore placebo: Placebo
Placebo, saline solution for sc injection
|
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Subjects in Clinical Remission at Week 6
Lasso di tempo: Week 6
|
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Subjects Achieving a Clinical Response at Week 6
Lasso di tempo: Week 0, Week 6
|
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
Lasso di tempo: Week 6
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 6
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
Lasso di tempo: Week 0 to Week 6
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 6
|
|
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
Lasso di tempo: Week 0 to Week 6
|
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item).
The first three items are scored for the previous day.
Lower scores indicated better well being.
|
Week 0 to Week 6
|
|
Percentage of Subjects in Clinical Remission at Week 2
Lasso di tempo: Week 2
|
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 2
|
|
Percentage of Subjects in Clinical Remission at Week 4
Lasso di tempo: Week 4
|
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 4
|
|
Percentage of Subjects Achieving a Clinical Response at Week 2
Lasso di tempo: Week 0, Week 2
|
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 2
|
|
Percentage of Subjects Achieving a Clinical Response at Week 4
Lasso di tempo: Week 0, Week 4
|
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
Lasso di tempo: Week 0 to Week 2
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 2
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
Lasso di tempo: Week 0, Week 4
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
Lasso di tempo: Week 2
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 2
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
Lasso di tempo: Week 4
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 4
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Lasso di tempo: Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Lasso di tempo: Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Lasso di tempo: Week 0, Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Lasso di tempo: Week 0, Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Pubblicazioni generali
- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.
- Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.
- Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930. Epub 2014 Aug 22.
Collegamenti utili
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 marzo 2008
Completamento primario (Effettivo)
1 ottobre 2009
Completamento dello studio (Effettivo)
1 novembre 2009
Date di iscrizione allo studio
Primo inviato
18 ottobre 2007
Primo inviato che soddisfa i criteri di controllo qualità
31 ottobre 2007
Primo Inserito (Stima)
1 novembre 2007
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
9 agosto 2018
Ultimo aggiornamento inviato che soddisfa i criteri QC
10 luglio 2018
Ultimo verificato
1 ottobre 2011
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- C87085
- 2007-001913-41 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .